Literature DB >> 22496943

Papillary cystadenocarcinoma of ovary presenting as obstructive jaundice: a rare presentation.

Amit Gupta, Athiko L Noba, Sweety Gupta, Vinod K Arora, Vinita Rathi, Sunil Kumar.   

Abstract

Obstructive jaundice resulting from malignancy of gastrointestinal tract and hepatobiliary tract has been reported in various studies. Ovarian malignancy leading to obstructive jaundice due to portal lymphadenopathy is of rare occurrence. We report a case presented with obstructive jaundice and on further evaluation, found to have ovarian papillary cyst adenocarcinoma with secondaries at porta hepatis which was managed successfully by neoadjuvant chemotherapy followed by cytoreductive surgery.

Entities:  

Keywords:  Obstructive jaundice; Ovarian carcinoma; Papillary cystadenocarcinoma; Portal lymphadenopathy

Year:  2012        PMID: 22496943      PMCID: PMC3321329          DOI: 10.5001/omj.2012.32

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  4 in total

1.  Carcinoma of the ovary. A clinicopathological study of 86 autopsied cases with special reference to mode of spread.

Authors:  F Bergman
Journal:  Acta Obstet Gynecol Scand       Date:  1966       Impact factor: 3.636

2.  Carcinoma of the ovary presenting as obstructive jaundice.

Authors:  M Rosenblatt; S Zafaranloo; M L Tancer
Journal:  Gynecol Oncol       Date:  1989-03       Impact factor: 5.482

Review 3.  Biliary tract obstruction secondary to cancer: management guidelines and selected literature review.

Authors:  J J Lokich; R A Kane; D A Harrison; W V McDermott
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

4.  Extrahepatic biliary obstruction secondary to metastatic cancer.

Authors:  J H Thomas; G E Pierce; C Karlin; A S Hermreck; R I MacArthur
Journal:  Am J Surg       Date:  1981-12       Impact factor: 2.565

  4 in total
  1 in total

Review 1.  Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer.

Authors:  Takeshi Okamoto
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.